We use cookies to collect and analyse information on site performance and usage to improve and customise your experience, where applicable. View our Cookies Policy. Click Accept and continue to use our website or Manage to review and update your preferences.

Pinsent Masons advises Sandoz on Irish deal
Neil Keenan

06 Mar 2024 / business Print

Pinsent Masons advises Sandoz on Irish deal

Pinsent Masons has advised generic and bio-similars company Sandoz on the acquisition of the remaining shares in Rowex Limited.

Rowex is a joint venture in Ireland between Sandoz and Rowa Pharmaceuticals.

Sandoz is headquartered in Basel, Switzerland, and reaches 500 million patients a year globally.

Rowex, based in Bantry, Co Cork, is one of Ireland’s leading providers of generic and over-the-counter (OTC) medicines, supplying the Irish market with branded generic pharmaceuticals.

‘Significant strategic acquisition’

The acquisition builds on a 30-year joint venture in Ireland with Rowa Pharmaceuticals and results in Sandoz’s full expansion into the market as a wholly owned business in Ireland.

The Pinsent Masons team was led by Dublin-based corporate partner Neil Keenan, London-based IP partner Gina Bicknell, and Dublin-based corporate senior associate Dorian Rees.

The firm provided advice to Sandoz on corporate, employment, tax, regulatory, competition, property, data-protection, and intellectual-property-law matters.

Keenan described the deal as “a significant strategic acquisition” in the Irish healthcare market for Sandoz, a long-standing client of the firm.

Gazette Desk
Gazette.ie is the daily legal news site of the Law Society of Ireland